NEXTBio Capital Management LP Acquires Shares of 95,485 Vaxcyte, Inc. $PCVX

NEXTBio Capital Management LP acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 95,485 shares of the company’s stock, valued at approximately $4,406,000. Vaxcyte accounts for approximately 2.6% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 16th biggest position.

A number of other institutional investors have also recently bought and sold shares of PCVX. Smartleaf Asset Management LLC grew its stake in Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after buying an additional 184 shares during the period. Allworth Financial LP raised its stake in shares of Vaxcyte by 148.9% in the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after buying an additional 731 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new position in shares of Vaxcyte during the 3rd quarter valued at $45,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Performance

Shares of PCVX opened at $47.46 on Friday. The business has a 50-day moving average of $54.28 and a 200 day moving average of $52.66. Vaxcyte, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $65.00. The firm has a market cap of $6.85 billion, a P/E ratio of -6.90 and a beta of 1.24.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter in the prior year, the company posted ($1.04) earnings per share. As a group, research analysts predict that Vaxcyte, Inc. will post -7.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Jim Wassil sold 2,250 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the transaction, the chief operating officer directly owned 158,494 shares in the company, valued at approximately $7,848,622.88. This trade represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction of $180,000.00. Following the completion of the transaction, the chief accounting officer owned 28,975 shares of the company’s stock, valued at $1,738,500. This trade represents a 9.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 9,392 shares of company stock worth $524,426. 3.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

PCVX has been the subject of several recent research reports. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Finally, BTIG Research lifted their price objective on Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Vaxcyte has a consensus rating of “Moderate Buy” and an average target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.